Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Clinical Infectious Diseases

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1660347

This article is part of the Research TopicLeveraging Real-Time Genomic Surveillance to Combat Infectious Diseases and Antimicrobial ResistanceView all 13 articles

Nanopore Targeted Sequencing in Lower Respiratory Infections: A Retrospective Study on Diagnostic Applications, Clinical Characterization, and Antimicrobial Guidance

Provisionally accepted
Qian  ChenQian Chen1Yifan  QiuYifan Qiu1Jintao  ZhangJintao Zhang2Shilong  ChenShilong Chen2Xinjun  HanXinjun Han1Qingshi  ZengQingshi Zeng2Guanghai  WangGuanghai Wang2Xiang  JiXiang Ji2Dong  LiangDong Liang2*
  • 1Shandong University, Jinan, China
  • 2Shandong Provincial Qianfoshan Hospital, Jinan, China

The final, formatted version of the article will be published soon.

Objective This study aims to evaluate the pathogen detection and diagnostic performance of Nanopore targeted sequencing (NTS) versus conventional microbiological tests (CMTs) in patients with suspected lower respiratory infections (LRIs). It also explores the clinical characteristics of patients with discrepant detection results and analyzes the clinical significance of antimicrobial resistance (AMR) gene detection using NTS. Methods A retrospective analysis was performed on patients with suspected LRIs admitted to the Department of Respiratory and Critical Care Medicine at Shandong Provincial Qianfoshan Hospital from January 2023 to January 2024. Bronchoalveolar lavage fluid (BALF) and sputum samples were collected from enrolled patients and subjected to both CMTs and NTS. Results This retrospective study included 70 suspected LRIs patients (66 BALF, 4 sputum samples), with 56 diagnosed as LRIs, 12 as non-infectious diseases, and 2 undetermined. CMTs detected 14 pathogens, This is a provisional file, not the final typeset article while NTS identified 76. NTS showed higher complete (73.21% vs. 16.07%) and partial (23.21% vs. 35.71%) diagnostic rates than CMTs. Diagnostic metrics favored NTS: sensitivity (96.43% vs. 69.64%), NPV (75.00% vs. 32.00%), Youden index (0.464 vs. 0.363), and AUC (0.732 vs. 0.682), though CMTs had higher specificity (66.67% vs. 50.00%) and PPV (90.70% vs. 90.00%). Patients with concordant positive results (CMTs+NTS+) exhibited more severe clinical features and inflammatory markers than NTS-single positive cases, and had higher exposure to invasive procedures—an confirmed independent risk factor. NTS detected 16 resistance genes in 15 patients, with high ESKAPE pathogen coverage. Conclusion NTS overcomes the technical limitations of traditional methods for fastidious pathogens (e.g., intracellular bacteria, mycobacteria) and mixed infections, providing robust technical support for precision anti-infective therapy and complex infection pathogen tracing. Notably, NTS is particularly suitable for early diagnosis in patients with mild symptoms or intact immune function. Compared with CMTs, NTS's highly efficient and sensitive detection capabilities hold significant practical implications for early infection source isolation, nosocomial outbreak prevention, and optimization of antibacterial drug management strategies.

Keywords: Nanopore targeted sequencing, conventional microbiological tests, lower respiratoryinfections, Bronchoalveolar Lavage Fluid, antimicrobial resistance

Received: 05 Jul 2025; Accepted: 14 Oct 2025.

Copyright: © 2025 Chen, Qiu, Zhang, Chen, Han, Zeng, Wang, Ji and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dong Liang, dl5506@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.